Kopeerime ingliskeelse teate; eestikeelne tõlge tuleb veidi hiljem.

Hetkel on test alles katsestaadiumis, kuid soovijatel on juba võimalik koeri testida. Ühe koera testimine maksab 105 eurot.


The researchers asked that the message be passed on to the international Berner community.


We are happy to let you know that we developed a genetic risk "pre-test" for Histiocytic sarcoma in the Bernese Mountain dog populations (see below).

The genetic markers and statistical analysis have been elaborated by Benoit Hedan in our team, mainly with data and samples from French Bernese Mountain Dogs and in this context, the next step will be to validate this test in other European populations.

To inform European Bernese Mountain clubs, we sent this e-mail to our contacts (present and previous), but we do not have systematically the "health" contact / President for all European Clubs, please pass on our message and we do of course apologize for those who are not on the first list.

We hope this e-mail finds you well and we wish you all the best.

Catherine André & Benoit Hedan



Information to European Bernese Mountain dogs (BMD) Clubs and Societies

The "Dog genetics team" of CNRS of Rennes and ANTAGENE laboratory (France) have worked together to provide breeders with a first genetic "pre-test" to estimate the risk of developing and transmitting histiocytic sarcoma in Bernese Mountain Dogs (BMD). We expect that this tool will help breeders to progressively reduce the frequency of histiocytic sarcoma in BMDs.

Following several years of international collaborative research histiocytic sarcoma*; - at CNRS (Rennes, France), we considered that the first genetic results could be used to provide breeders with a pre-test, useful for selection in their kennel. Using genetic and genealogical data from over 1000 BMDs, mostly from France, we selected nine markers, which allow to estimate a risk in the context of a kennel. We validated their use with the recent collaboration of the French BMD club (AFBS) and several French breeders.

Presently this pre-test is exclusively available to BMDs breeders and validated for BMDs of the French population. This pre-test is intended to help breeders in their selection and should be used as a selection factor among others (Hip dysplasia, beauty, behaviour, other health characteristics...). It is not a predictive test for histiocytic sarcoma on single dogs. The correct use of this pre-test, on males and females for reproduction as well as puppies to select the best offsprings for the next generation, aims to help breeders to adapt their breeding programs, to reduce the risk of developing and transmitting histiocytic sarcoma in their breeding lines, and more widely, the incidence of this cancer in the population of BMDs.

To validate this DNA pre-test on several European populations of BMDs, in order to enlarge its use to other BMD populations, we need the involvement of BMD clubs from each country. Thus, we're asking your help to inform breeders and to collect blood samples (5ml on EDTA tubes) of 30 old healthy BMDs (> 10 years old) and 30 affected BMDs from your country.

Should you require any further information, please do not hesitate to contact us (Benoit and /or myself).

* The collaborative research is performed since many years between the "dog genetics team", CNRS (Centre National de la Recherche Scientifique of Rennes, France) and international teams of Dr. Elaine Ostrander (NIH, National Institutes of Health, U.S.) and Dr. Matthew Breen (NCSU, U.S.), thanks to the financial support of the AKC-CHF, of the French BMD club (AFBS), the SIBB Italian Club and the DCBS German Club.


Catherine André and Benoit Hedan

Dog genetics team, CNRS Rennes, France

Dr. Catherine André

Equipe "Génétique du chien"

"Institut de Génétique et Développement de Rennes"

UMR6290-CNRS, Université de Rennes 1

2, Av. Léon Bernard

35043 Rennes cedex


From the Antegene website: www.antagene.com/fr/commander/pre-test-sh


Histiocytic sarcoma (formerly malignant histiocytosis) is a major cause of death in the Bernese Mountain Dog. It is a cancer of histiocytes, cells responsible for immune function, present in many organs and glands. No treatment is effective to date, and is fatal.

How to Diagnose histiocytic sarcoma?

Currently, the only definitive diagnosis is histological analysis (sampling of the tumor in formalin, sent to standard laboratory by your veterinarian).

What causes this cancer? Why is it so common?

The development of this cancer involves several genes and environmental factors, which makes it very complex transmission mode.

It appears late, often after the dog breeds and therefore transmitted susceptibility genes to offspring, contributing to the spread of the disease.

For over eight years, the team Genetics Dog CNRS Rennes and colleagues are conducting a genetic study on histiocytic sarcoma in the Bernese Mountain Dog.

The analysis of a cohort of dogs allowed to highlight regions of the genome involved in this disease and to identify genetic markers associated with risk of developing and transmitting cancer. Studies continue to explore the genes in these regions.

This research has raised a number of samples (more than 1,000 Bernese mountain dogs) of dogs with old but healthy dogs. Thanks to a large family tree of more than 300 dogs, including 150 with and monitoring of dogs developed this cancer, we were able to characterize the epidemiology, clinical signs and analysis suggest oligogenic mode of transmission of this disease where only a small number of genes are involved.

This study is the result of longstanding collaborations in France and abroad between teams of researchers, veterinarians, breed clubs and many breeders and owners.

To learn more about the search, click here


To benefit breeders of the first search results on histiocytic sarcoma in the Bernese, the ANTAGENE, in collaboration with the CNRS Genetics Dog Rennes, has developed a pre-test.

The pre-test HS delivers a genetic index is based on the statistical analysis of genetic markers from the research data. It is a screening tool and not a predictive test for the development of this cancer. The pre-test SH is a genetic tool to assist breeders in managing their farms and couplings to reduce the incidence of histiocytic sarcoma in the population of Bernese mountain dogs.

The genetic index is based on nine genetic markers (panel SH0912) from the data of scientific research on the histiocytic sarcoma in the Bernese Mountain Dog. The method of calculating the index were developed from a population of 1081 European dogs, mainly French.

• The index has three possible outcomes:

Index Explanation

A Individuals are four times less likely to develop the histiocytic sarcoma

B Index neutral

C Individuals are four times more likely to develop histiocytic sarcoma. The risk of transmission of markers associated with the disease has increased

• use index Tips for breeders

It is important in a family of favor individuals with the best clues as future breeders.

It is essential in your choice of matings and selection to maintain sufficient genetic diversity within the breed, this index is only one selection criterion among others.

• Recommendations

C with a dog also other qualities should not be removed from the breeding but coupled with individuals A or B. Selections should be made to avoid breeding C x C.

As a screening tool, the pre-test SH is only available to breeders.

What are the terms of the pre-test SH?

• Download and sign two copies of the Memorandum of Understanding


- The collection of blood in EDTA (buccal swab accepted for puppies less than 3 months)

- The certificate collection ANTAGENE completed, signed and stamped by the veterinarian

- Payment or proof of payment of an amount of € 105 per pre-ordered test

- A signed copy of the Memorandum of Understanding (in the first order)

• To help the research, send a copy of the pedigree ANTAGENE and submit regularly, and for each dog, the clinical follow-up questionnaire online (click here) www.antagene.com/fr/contact/questionnaire-clinique-sh

• The result is communicated only by mail in within 4 to 6 weeks